Eleven Biotherapeutics Inc. (EBIO) Reaches New 52-Week High at $5.77
Shares of Eleven Biotherapeutics Inc. (NASDAQ:EBIO) reached a new 52-week high on Monday . The company traded as high as $5.77 and last traded at $5.50, with a volume of 7,088,197 shares trading hands. The stock had previously closed at $4.71.
The firm’s market cap is $83.28 million. The firm’s 50 day moving average price is $3.18 and its 200-day moving average price is $1.45.
Eleven Biotherapeutics (NASDAQ:EBIO) last issued its quarterly earnings results on Friday, August 12th. The biopharmaceutical company reported ($0.33) EPS for the quarter. Analysts anticipate that Eleven Biotherapeutics Inc. will post ($1.75) EPS for the current year.
In related news, major shareholder Boxer Capital, Llc sold 1,042,000 shares of the stock in a transaction dated Monday, June 13th. The stock was sold at an average price of $2.74, for a total value of $2,855,080.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.